Poolbeg Pharma's Capital-Light Model For New Anti-Infectives Development
UK Spin Out Completes IPO And Will List On AIM
Executive Summary
A new UK company, Poolbeg Pharma, has been set up to develop new anti-infectives in an efficient manner, and already has a repositioned MAP kinase inhibitor for the treatment of severe influenza ready for Phase II studies.